Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04297124 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04297124 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 8 participants.
The verdict
NCT04297124, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
CC-90009-CP-001 is a Phase 1, single-center, open-label, clinical pharmacology study to measure how much CC 90009 gets into the bloodstream, how much is eliminated in urine and stool, and how long it takes the body to get rid of it. In addition, the safety and tolerability of CC 90009 will be evaluated.
Interventions
- RADIATION [14C]
- DRUG CC-90009
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-03-11 |
| Est. Completion | 2021-06-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04297124
The ClinicalTrials.gov registry entry for NCT04297124 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which [14C] is the first listed.
NCT04297124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04297124 about?
NCT04297124 is a clinical study titled "A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects". CC-90009-CP-001 is a Phase 1, single-center, open-label, clinical pharmacology study to measure how much CC 90009 gets into the bloodstream, how much is eliminated in urine and stool, and how long it takes the body to get rid of it. In addition, the safety and tolerability of CC 90009 will be evalua...
What is the current status of trial NCT04297124?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2020-03-11. Estimated completion is 2021-06-04.
What interventions are being tested in trial NCT04297124?
The interventions under investigation include: [14C] (RADIATION), CC-90009 (DRUG).
Who is sponsoring clinical trial NCT04297124?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.